Romosozumab Improves Tissue Thickness–Adjusted Trabecular Bone Score in Women With Osteoporosis and Diabetes
Authors' conclusion
In postmenopausal women with osteoporosis and T2D, 12 months of romosozumab followed by 24 months of alendronate vs alendronate alone significantly improved LS aBMD and TBSTT (independently of abdominal fat) and to a greater extent. Hence, romosozumab may improve bone strength in patients with T2D.
Study context
- Population
- Women from ARCH with T2D at baseline and lumbar spine (LS) DXA scans at baseline and ≥1 postbaseline visit
- Participants
- 165 vs 195
- Comparison
- Romosozumab 12 months then alendronate 24 months vs alendronate alone 36 months
- Romosozumab-to-alendronaten = 165
- Alendronate-to-alendronaten = 195reference
- Primary endpoint
- LS aBMD and tissue thickness-adjusted trabecular bone score (TBS) (TBSTT)
- Follow-up
- Months 12, 24 and 36
Primary result
As reported in the abstract
LS aBMD and TBSTT gains
- Significantly greater gains in LS areal bone mineral density (aBMD) and TBSTT with romosozumab vs alendronate at month 12, maintained after transition to alendronate and persisting significantly at months 24 and 36
Further findings
| Outcome | Romosozumab-to-alendronate | Alendronate-to-alendronate |
|---|---|---|
| Correlation of TBSTT % changes with LS aBMD % changes (weak) · baseline to month 36 | R2 0.1493 | R2 0.0429 |
Original publication
Romosozumab Improves Tissue Thickness–Adjusted Trabecular Bone Score in Women With Osteoporosis and Diabetes. J Clin Endocrinol Metab. Published 24 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →